Table 2.
Change from baseline to end of double-blind phase (full analysis sample)
| Least squares mean (95% CI) | ||||
|---|---|---|---|---|
| Pancreatin (n = 31)* | Placebo n = 25)* | Treatment difference | P-value (ancova) | |
| CFA,% | 21.4 (13.7, 29.2) | −4.2 (−12.8, 4.5) | 25.6 (13.9, 37.3) | <0.001 |
| CNA,% | 18.9 (10.6, 27.3) | −10.3 (−19.6, −1.0) | 29.2 (16.7, 41.8) | <0.001 |
| Stool fat, g/day | −24.0 (−30.7, −17.3) | 6.1 (−1.3, 13.6) | 30.2 (40.2, 20.1) | <0.001 |
ancova, analysis of covariance; CFA, coefficient of fat absorption; CI, confidence interval; CNA, coefficient of nitrogen absorption.
*
There were no stool analysis data at the end of the double-blind period for one subject in the pancreatin group and one subject in the placebo group.